Atropine: Nursing Drug Guide, Bradycardia Dosing & Monitoring

Atropine sulfate is supplied generically for injection and ophthalmic use. Verify vial strength—concentration errors (0.4 mg/mL vs 1 mg/mL prefilled syringes) are a common source of under- or overdosing.

Common presentation: Atropine sulfate injection (multiple concentrations). Not interchangeable with: glycopyrrolate or scopolamine for antisialagogue orders—confirm the MAR drug name before administration.

Atropine increases heart rate by blocking vagal (muscarinic) effects on the SA and AV nodes. Nursing priorities differ by indication—symptomatic bradycardia dosing is not the same as organophosphate poisoning titration or preoperative antisialagogue use.

↔On a small screen, swipe or scroll sideways to see the full table.

Atropine competitively antagonizes acetylcholine at muscarinic receptors, reducing vagal tone on the heart and increasing SA node automaticity and AV conduction. Peripheral effects include decreased secretions, mydriasis, and decreased GI motility. In denervated (transplanted) hearts, vagal blockade may not increase rate—do not rely on atropine alone. Mexiletine may delay atropine absorption when given together per labeling.

Symptomatic bradycardia (adults): 0.5 mg IV or IM, or 1–2 mg endotracheally per protocol; repeat every 3–5 minutes as needed. Do not exceed 3 mg total for this indication—if no response, initiate transcutaneous pacing per ACLS.

Organophosphate poisoning: Initial 1–6 mg IV, IM, or ET; repeat every 3–5 minutes and may double doses until secretions dry and atropinization is achieved. Maintenance infusion may follow per toxicology protocol—this pathway has no bradycardia-style 3 mg ceiling.

Pediatrics (symptomatic bradycardia)

0.02 mg/kg IV/IO; repeat every 5 minutes as needed per pediatric ACLS. Use weight-based calculations and independent double-check—pediatric concentration errors are high-risk.

Coronary artery disease limits

In patients with coronary artery disease or ischemic heart disease, labeling warns to limit total dose to 0.03–0.04 mg/kg (approximately 2–3 mg maximum). Atropine can provoke tachycardia that increases myocardial oxygen demand—monitor for angina or ischemic ECG changes after each dose.

Missed dose: Not applicable for emergent bradycardia boluses—document cumulative mg given toward the 3 mg maximum.

Pretreatment checks

• Review 12-lead ECG recording and monitor rhythm—confirm not Mobitz II, third-degree AV block, or wide-complex bradycardia
• Verify indication (bradycardia vs antisialagogue vs poisoning)—dose ceilings differ
• Independent double-check vial concentration (mg/mL) and total mg; perform medication reconciliation for anticholinergics and cardiac glycosides
• Screen for glaucoma (especially narrow-angle), urinary retention, and CAD history

Contraindications / warnings

Contraindications: None listed per Fresenius Kabi labeling—apply clinical warnings below instead of treating the drug as unconstrained.

Warnings and cautions

• Mobitz type II second-degree AV block, third-degree block, or wide-complex bradycardia—use pacing, not atropine
• Asymptomatic bradycardia—treat the cause; atropine is for perfusion compromise
• Transplanted heart—may not respond; prepare pacing
• Known hypersensitivity; caution with anaphylaxis history if co-administered with other agents

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Routes: IV, IM, SC, endotracheal (per protocol)—verify route on the MAR matches indication.

• Bradycardia: give 0.5 mg IV push via patent line; may repeat every 3–5 minutes to max 3 mg total
• Use IV bolus administration technique with cardiac monitoring—atropine is not an infusion for bradycardia
• Follow high-alert medication administration double-checks for concentration and cumulative dose tracking

• Heart rate increase within minutes for responsive sinus or nodal bradycardia
• Improved blood pressure, mental status, and symptom relief when bradycardia caused hypoperfusion
• Mild anticholinergic effects: dry mouth, blurred vision, decreased secretions
• No improvement in Mobitz II, third-degree block, or transplanted heart—expect pacing pathway instead

• HR >100–120/min with chest pain in CAD patient after atropine—hold further doses; obtain ECG; notify prescriber
• Agitation, confusion, hallucinations, or urinary retention after cumulative dosing—anticholinergic toxicity; prescriber/toxicology pathway
• Worsening AV block or wide-complex rhythm after dose—stop atropine; prepare pacing and rapid response activation
• Dizziness with HR still <40 after 3 mg total—pacing indicated, not more atropine
• Acute angle-closure glaucoma symptoms (severe eye pain, halos)—ophthalmic emergency

↔On a small screen, swipe or scroll sideways to see the full table.

Anticholinergic toxicity presents with hyperthermia, flushed dry skin, tachycardia, ileus, urinary retention, mydriasis, and delirium. Severe poisoning may require ICU-level care.

Antidote

• Physostigmine 1–4 mg IV slowly for atropine overdosage (0.5–1 mg in children)—per prescriber/toxicology when clinically indicated and no contraindications (e.g., QRS prolongation from TCA co-ingestion)
• Diazepam or short-acting barbiturate for seizures per order
• Atropine is not removed by dialysis; supportive care includes cooling for hyperthermia and cardiac monitoring

• Atropine vs epinephrine—emergency cart drawers; read label in hand before bolus
• Concentration confusion—0.4 mg/mL vs 1 mg/mL; calculate total mg every time
• Bradycardia max vs poisoning titration—3 mg bradycardia ceiling does not apply to organophosphate protocols
• Atropine vs glycopyrrolate—antisialagogue orders may specify one agent only

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous cardiac rhythm, HR, BP before and after each dose
• Perfusion: mental status, urine output, symptoms of hypoperfusion
• Anticholinergic effects and cumulative dose (mg total toward 3 mg bradycardia max)
• ECG changes suggesting ischemia in CAD patients after HR increase

Document

• Pre-treatment rhythm, indication, concentration, mg given, route, and response at 3–5 minutes
• Cumulative atropine total and rationale if pacing initiated
• Patient teaching on temporary blurred vision and dry mouth

• “This medication may briefly speed up your heart and cause dry mouth or blurred vision—tell us if you have chest pain, confusion, or trouble urinating.”
• Report worsening eye pain or halos around lights immediately (glaucoma risk)
• Bedside call light within reach until steady on feet—anticholinergic effects increase fall risk
• Breastfeeding patients: pump and discard milk for 24 hours after IV atropine per LactMed guidance and prescriber plan

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and ACLS pathways.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice NCLEX-style clinical judgment practice for atropine using a tabbed postoperative bradycardia case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, post-dose trend interpretation, documentation cloze, repeat-dose judgment, and a matrix urgency item—recognise cues → analyse rhythm → prioritise → act → evaluate outcomes (HR response vs toxicity vs pacing need).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.